Literature DB >> 1933872

Follow-up study of twenty-four families with Li-Fraumeni syndrome.

J E Garber1, A M Goldstein, A F Kantor, M G Dreyfus, J F Fraumeni, F P Li.   

Abstract

The Li-Fraumeni cancer family syndrome is manifested by susceptibility to breast cancer, sarcomas, and other neoplasms in children and young adults. The present study utilized clinical follow-up data on 545 members of 24 Li-Fraumeni kindreds living and cancer-free at family ascertainment. Two hypotheses were tested based on a model of autosomal dominant genetic predisposition: (a) that syndrome cancers would continue to occur excessively during follow-up compared to the general population, and (b) that the tumors would occur primarily among those family members likely to carry the gene. Population cancer rates were compared with cancer rates in follow-up of the cohort from ascertainment to 1988. Risk of carrying the gene for the syndrome at the time of ascertainment was calculated for each family member under two models with somewhat different definitions of affection with the syndrome. Cancer occurrence after ascertainment was then analyzed according to the risks. Cancer did continue to occur excessively among the entire cohort during follow-up [relative risk (RR 2.1)]. The excess was greatest below age 20 (RR 21.1), declined with increasing age, and was most pronounced for neoplasms featured in the syndrome (RR 18.2). Among persons less than age 45, at least 87% of cancers occurred in those at higher risk of carrying the gene under both genetic models (RR 22.9 and 21.3). The clinical data, therefore, reliably identify individuals likely to carry a dominantly inherited gene conferring susceptibility to a specific constellation of neoplasms. Recent identification of a germ line mutation in the tumor suppressor gene p53 in persons with the syndrome may, if confirmed, have implications for ultimately defining the component tumors of the syndrome and for the causes and prevention of those tumors arising outside these families.

Entities:  

Mesh:

Year:  1991        PMID: 1933872

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Genetic counselors: translating genomic science into clinical practice.

Authors:  Robin L Bennett; Heather L Hampel; Jessica B Mandell; Joan H Marks
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 3.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

4.  Detection of functional single-nucleotide polymorphisms that affect apoptosis.

Authors:  Sandra L Harris; German Gil; Harlan Robins; Wenwei Hu; Kim Hirshfield; Elisabeth Bond; Gareth Bond; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

5.  BRCA1 and BRCA2 in breast cancer predisposition and recombination control.

Authors:  Ralph Scully; Anyong Xie
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

6.  Timing and context: important considerations in the return of genetic results to research participants.

Authors:  Kate A McBride; Nina Hallowell; Martin H N Tattersall; Judy Kirk; Mandy L Ballinger; David M Thomas; Gillian Mitchell; Mary-Anne Young
Journal:  J Community Genet       Date:  2015-05-26

7.  A multistage association study identifies a breast cancer genetic locus at NCOA7.

Authors:  Kathryn S P Higginbotham; Joan P Breyer; Kevin M Bradley; Peggy A Schuyler; W Dale Plummer; Marcia E Freudenthal; Amy Trentham-Dietz; Polly A Newcomb; Melinda E Sanders; David L Page; Fritz F Parl; Kathleen M Egan; William D Dupont; Jeffrey R Smith
Journal:  Cancer Res       Date:  2011-05-24       Impact factor: 12.701

8.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Authors:  Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

10.  Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Authors:  Shenying Fang; Ralf Krahe; Guillermina Lozano; Younghun Han; Wei Chen; Sean M Post; Baili Zhang; Charmaine D Wilson; Linda L Bachinski; Louise C Strong; Christopher I Amos
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.